- After being up as much as13% in today's session, Inovio (INO -14.2%) turns tail and plummets 24% from its intraday high of $12.20 on a 10x surge in volume. On a purely technical basis, the intensity of the bearish reversal should put longs on high alert.
- Earlier today the company announced the initiation of a Phase 1/2a clinical trial to evaluate the safety, immunogenicity and clinical responses of INO-3112, a combination immunotherapeutic candidate for HPV-associated head and neck cancer.
From other sites
Video at CNBC.com (Apr 8, 2015)
at CNBC.com (Nov 24, 2014)
Video at CNBC.com (Nov 24, 2014)
at CNBC.com (Oct 21, 2014)
at CNBC.com (Oct 2, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs